# Syngene International (NSE: SYNGENE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SYNGENE · Pivot · prices to 22 Oct 2026

Syngene International (NSE: SYNGENE) closed at ₹370.75 on 22 Oct 2026, down 1.12% on the day. With a market capitalisation of ₹14,966 Cr, it ranks 424th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.

At its last close the stock traded at 47× trailing earnings, against a return on equity of 6.5% in FY26. Over the past year the share price has fallen 40.8%. Its 52-week range is ₹344.45 (9 Oct 2026) to ₹678.95 (7 Jan 2026); the last close is 45.4% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹736 Cr (−15.8% year on year) and net profit −₹9 Cr (−110.4%), on a consolidated basis. Promoters held 52.59% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹370.75 |
| Market cap | ₹14,966 Cr |
| P/E (trailing) | 47 |
| ROE | 6.5% (FY26) |
| ROCE | 9.7% (FY26) |
| Debt to equity | 0 |
| 52-week high | ₹678.95 (7 Jan 2026) |
| 52-week low | ₹344.45 (9 Oct 2026) |
| 1-year return | −40.8% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹736 Cr | −15.8% | −₹9 Cr | −110.4% | −₹0.22 |
| Q4 FY26 | ₹1,037 Cr | +1.8% | ₹148 Cr | −19.3% | ₹3.68 |
| Q3 FY26 | ₹917 Cr | −2.8% | ₹15 Cr | −88.6% | ₹0.37 |
| Q2 FY26 | ₹911 Cr | +2.2% | ₹67 Cr | −36.8% | ₹1.67 |
| Q1 FY26 | ₹875 Cr | +10.7% | ₹87 Cr | +14.5% | ₹2.16 |
| Q4 FY25 | ₹1,018 Cr | +11.0% | ₹183 Cr | −2.8% | ₹4.56 |
| Q3 FY25 | ₹944 Cr | +10.6% | ₹131 Cr | +17.6% | ₹3.27 |
| Q2 FY25 | ₹891 Cr | −2.1% | ₹106 Cr | −8.9% | ₹2.64 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹3,739 Cr | ₹317 Cr |
| FY25 | ₹3,642 Cr | ₹496 Cr |
| FY24 | ₹3,489 Cr | ₹510 Cr |
| FY23 | ₹3,193 Cr | ₹464 Cr |
| FY22 | ₹2,604 Cr | ₹396 Cr |
| FY21 | ₹2,184 Cr | ₹405 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 52.59%
- Foreign institutions: 11.82%
- Domestic institutions: 28.02%
- Non-institutions: 7.14%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Alivus Life Sciences](https://app.pivotnow.in/stock/ALIVUS) | ₹1,272.00 | ₹15,612 Cr | 27.7 | — |
| [Alembic Pharmaceuticals](https://app.pivotnow.in/stock/APLLTD) | ₹785.00 | ₹15,430 Cr | 22.9 | — |
| [AstraZeneca Pharma India](https://app.pivotnow.in/stock/ASTRAZEN) | ₹6,056.00 | ₹15,140 Cr | 80.9 | — |
| [Poly Medicure](https://app.pivotnow.in/stock/POLYMED) | ₹1,479.10 | ₹14,992 Cr | 46.7 | — |
| [Jubilant Pharmova](https://app.pivotnow.in/stock/JUBLPHARMA) | ₹930.80 | ₹14,826 Cr | 37.1 | — |
| [Dr. Agarwal's Health Care](https://app.pivotnow.in/stock/AGARWALEYE) | ₹459.10 | ₹14,553 Cr | — | — |

## Questions and answers

### What is the share price of Syngene International today?

Syngene International (NSE: SYNGENE) last closed at ₹370.75 on 22 Oct 2026. Its 52-week high is ₹678.95 and its 52-week low is ₹344.45.

### What is the market cap of Syngene International?

Syngene International's market capitalisation is ₹14,966 Cr (₹14,966 Cr) at the 22 Oct 2026 close, ranking 424th among the NSE companies Pivot tracks.

### What is the P/E ratio of Syngene International?

Syngene International trades at a trailing P/E of 47. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 37.1.

### What is the ROE and ROCE of Syngene International?

Return on equity was 6.5% in FY26 and return on capital employed was 9.7% in FY26 (consolidated figures).

### Is Syngene International a debt-free company?

Syngene International is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Syngene International's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Syngene International reported revenue of ₹736 Cr, −15.8% year on year, and net profit of −₹9 Cr, −110.4% year on year.

### How has Syngene International stock performed over the last year?

Syngene International's share price has fallen 40.8% over the past year, −8.8% over three months and −3.8% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Syngene International?

As of 30 Jun 2026: promoters 52.59%, foreign institutions 11.82%, domestic institutions 28.02%, non-institutions 7.14%.

### Who are Syngene International's competitors?

The listed Pharma & Healthcare companies closest to Syngene International by market cap are Alivus Life Sciences, Alembic Pharmaceuticals, AstraZeneca Pharma India, Poly Medicure, Jubilant Pharmova and Dr. Agarwal's Health Care.

### Is Syngene International a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Syngene International's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SYNGENE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.